MarketLens

Investment Ideas

A Game Changer for Schizophrenia Treatment? Teva and Medincell's Olanzapine LAI Accepted by FDA

7 months ago

SHARE THIS ON:

A Game Changer for Schizophrenia Treatment? Teva and Medincell's Olanzapine LAI Accepted by FDA

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What Does Teva's Recent FDA Acceptance Mean for Investors

What Does Teva's Recent FDA Acceptance Mean for Investors

7 months ago

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

7 months ago

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

5 months ago

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

7 months ago

Category

Top Featured Pro Only Stock Analysis Investment Ideas ETFs Crypto

You may also like

Stock News•1 week ago

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Teva won FDA approval for WELTRUZA, a once-monthly subcutaneous olanzapine injectable for schizophrenia, adding a long-acting option to its neuropsychiatry portfolio.

Stock News•3 weeks ago

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Definium Therapeutics reported Phase III DT120 results showing statistically significant improvements in generalized anxiety disorder and major depressive disorder after a single treatment, with longe...

Stock News•3 months ago

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

TG Therapeutics launched a Phase 2 trial of BRIUMVI in ~60 treatment-resistant schizophrenia patients, based on emerging evidence linking immune dysfunction to the disease.

Breaking News

Convertible Bonds

Debt/Share Issuance

Dividend Announcements

Forward Guidance Revisions

Guidance Updates

Valuation Multiples

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

2 months ago

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

2 months ago

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

2 months ago

Top Headlines

Stock News•57 minutes ago

Amazon's new Bee AI devices have a bystander problem, says former AWS security engineer

Stock News•1 hour ago

Here's Why ServiceNow (NOW) Fell More Than Broader Market

Stock News•1 hour ago

Salesforce (CRM) Suffers a Larger Drop Than the General Market: Key Insights

Stock News•1 hour ago

1 Obvious Metric That Makes Nvidia a Top Stock to Buy Now

Stock News•1 hour ago

S&P 500 Snapshot: Stocks Slide Nearly 2% for the Week